INVESTORS & MEDIA
News Release
Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol
TARRYTOWN, N.Y. and
All six trials, ODYSSEY LONG TERM, COMBO I, ALTERNATIVE, OPTIONS I, OPTIONS II, and HIGH FH, met their primary efficacy endpoint of a greater reduction in LDL-C at 24 weeks, versus either active comparator or placebo, which included standard-of-care therapy. Detailed results from these trials were presented as part of a special session on the ODYSSEY program today, and on
"In these trials patients treated with alirocumab achieved significant and robust LDL-C reductions compared to baseline," said
The trials assessed alirocumab in hypercholesterolemic patients who were at high cardiovascular (CV) risk, had an inherited form of high cholesterol known as heterozygous familial hypercholesterolemia (HeFH), and/or a history of intolerance to two or more statins, including one at the lowest dose. All patients received alirocumab in addition to standard-of-care lipid-lowering therapy, with the exception of some patients in ODYSSEY ALTERNATIVE.
Table 1: Summary of Primary Efficacy Endpoint and Most | ||||
Common Adverse Events (AEs) | ||||
Study |
Patient group |
Primary efficacy endpoint (percent change from baseline in LDL-C at 24 weeks) |
Most common AEsa | |
Alirocumab |
Comparator | |||
LONG TERM Alirocumab (n=1,553)
|
All patients (high (total n=2,341) |
61 percent reduction |
1 percent increase |
Nasopharyngitis, upper respiratory tract infection, injection site reactions, influenza, diarrhea, urinary tract infection, bronchitis, myalgia, headache, back pain, arthralgia |
HeFH subgroup
|
56 percent reduction |
7 percent increase (placebo)d | ||
Non-HeFH subgroup
|
62 percent reduction |
0.5 percent reduction | ||
COMBO I Alirocumab (n=209)
|
High CV risk |
48 percent reduction |
2 percent reduction (placebo)c |
Upper respiratory tract infection, nasopharyngitis, urinary tract infection, dizziness, sinusitis, injection-site reaction |
OPTIONS I [Baseline statin = atorvastatin 20/40 mg]
|
High CV risk |
44-54 percent reduction |
- 20.5-23 percent reduction (ezetimibe)g |
Nasopharyngitis, upper respiratory tract infection, hypertension, back pain |
OPTIONS II [Baseline statin = rosuvastatin 10/20 mg]
Alirocumab (n=103)
|
High CV risk |
36-51 percent reduction |
- 11-14 percent reduction (ezetimibe)h - 16 percent reduction (double statin dose)h |
Nasopharyngitis, upper respiratory tract infection, hypertension, back pain |
ALTERNATIVE Alirocumab (n=126)
|
High CV risk and history of intolerance to two or more statins |
45 percent reduction |
15 percent reduction (ezetimibe)c |
Myalgia, nasopharyngitis, arthralgia, upper respiratory tract infection, headache, fatigue |
HIGH FH Alirocumab (n=72) vs. placebo (n=35)
|
HeFH |
46 percent reduction |
7 percent reduction (placebo)c |
Nasopharyngitis, injection-site reaction, diarrhea, sinusitis, bronchitis, headache, fatigue |
a. |
Occurred in at least 5 percent of alirocumab-treated patients |
b. |
Previously reported in |
c. |
P less than 0.0001 |
d. |
95 percent confidence interval of the LS mean difference vs. placebo: 57.5-69 percent reduction |
e. |
95 percent confidence interval of the LS mean difference vs. placebo: 59-64 percent reduction |
f. |
45 patients on atorvastatin 40 mg starting dose switched to rosuvastatin 40 mg |
g. |
For patients on atorvastatin 20 mg starting dose p=0.0004; for patients on atorvastatin 40 mg starting dose p less than 0.0001 |
h. |
For patients on rosuvastatin 10 mg starting dose p less than 0.0001; patients on rosuvastatin 20 mg starting dose did not reach statistical significance |
In a pre-specified interim analysis of the ongoing, 78-week ODYSSEY LONG TERM safety, tolerability and efficacy trial, a generally comparable rate of AEs was observed among the 37 percent (n=562) of alirocumab-treated patients who achieved two consecutive LDL-C values of less than 25 mg/dL, as compared to the overall alirocumab patient population in this trial.
ODYSSEY ALTERNATIVE is the first trial of a PCSK9 inhibitor to reassess statin intolerance, as measured by skeletal muscle AEs, by including a validation arm (atorvastatin 20 mg). In clinical practice, 10 to 25 percent of patients report intolerance to statins, and many have poorly-controlled LDL-C, which puts them at greater risk of CV events.1,2 In this trial, there were fewer skeletal muscle AEs in the alirocumab group compared to patients treated with atorvastatin (32.5 percent versus 46 percent, hazard ratio = 0.61; nominal p value = 0.042), and there was no significant difference when compared to the ezetimibe group (41 percent). In addition, there were numerically fewer discontinuations for skeletal muscle AEs in the alirocumab group, but this did not reach statistical significance (alirocumab 16 percent, ezetimibe 20 percent, atorvastatin 22 percent). In comparison, the overall rate of discontinuations for skeletal muscle AEs across the Phase 2 and 3 alirocumab placebo-controlled studies, where the majority of patients were also on statins, was 0.4 percent for alirocumab (n=2,476) and 0.5 percent for placebo (n=1,276).
Patients in all six randomized, double-blind, Phase 3 ODYSSEY trials received alirocumab via a single, self-administered 1-mililter (mL) subcutaneous injection, every two weeks. Alirocumab-treated patients received the 150 milligram (mg) dose in ODYSSEY LONG TERM and HIGH FH, and the 75 mg dose (increasing to 150 mg if needed to reach pre-specified LDL-C levels) in ODYSSEY ALTERNATIVE, OPTIONS I, OPTIONS II, and COMBO I. In the trials that used an individualized approach with 75 mg and 150 mg doses, the majority of patients reached their LDL-C goal while remaining on the 75 mg dose. Average baseline LDL-C levels in all six trials were between approximately 100-120 mg/dL, with the exception of ODYSSEY ALTERNATIVE and HIGH FH where baseline LDL-C levels were greater than 190 mg/dL.
The six ODYSSEY trials reported at AHA Scientific Sessions 2014, along with results from four other Phase 3 studies, encompass more than 5,000 patients studied in double-blind trials for 24-104 weeks. Regulatory submissions are planned in the U.S. and EU before the end of this year.
The ODYSSEY clinical trial program is ongoing. Click here for more information on alirocumab, LDL-C, and the ODYSSEY studies presented at the AHA Scientific Sessions 2014. Alirocumab is currently under clinical development and its safety and efficacy have not been evaluated by any regulatory authority.
About
About
Regeneron is a leading science-based biopharmaceutical company based in
References: | |
1. |
Bruckert E, Hayem G, Dejager S, et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients —the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403-414. |
2. |
Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding statin use in America and gaps in patient education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012 May-Jun;6(3):208-15. |
Sanofi Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking
information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of
Regeneron Forward-Looking Statements
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of
Contacts |
|
Media Relations |
Investor Relations |
|
|
Tel: +33 (0) 1 53 77 94 74 |
Tel: +33 (0)1 53 77 45 45 |
Mobile: +33 (0) 6 78 52 05 36 |
|
|
|
|
|
Mobile (onsite at AHA): +1 (908) 340-7811 |
|
Contacts Regeneron: |
|
Media Relations |
Investor Relations |
|
|
Mobile (onsite at AHA): +1 (914) 260-8788 |
Tel: +1 (914) 847-7799 |
|
|
Mobile (onsite at AHA): +1 (917) 929-1734 |
|
SOURCE
News Provided by Acquire Media